Meeting
2021 ASCO Annual Meeting
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
Authors
Zhongwei Zhao
Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Affiliated Lishui Hospital of Zhejiang University/the Fifth Affiliated Hospital of Wenzhou Medical University /The Central Hospital of Zhejiang Lishui, Lishui, China
Zhongwei Zhao , Wenyuan Guo , Shiji Fang , Shaohua Song , Jingjing Song , Fei Teng , Liyun Zheng , Jianting Mao , Hao Guo , Wang Huajing , Xiaofeng Feng , xiaowen he , Guoshan Ding , Jiansong Ji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
ChiCTR1900028121
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4095)
DOI
10.1200/JCO.2021.39.15_suppl.4095
Abstract #
4095
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).
First Author: Bo Zhai
Poster
2022 ASCO Annual Meeting
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
First Author: Sarah Marie Larson
Poster
2019 ASCO Annual Meeting
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
First Author: Hui Liu
Poster
2023 ASCO Annual Meeting
Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.
First Author: Samer Ali Srour